Búsqueda avanzada
Noticias (11)
Empresas (1)
Annexin Pharmaceuticals AB (publ) es una empresa de biotecnología con sede en Suecia. Su principal producto es ANXV, una proteína humana recombinante Annexin A5, para el tratamiento de urgencia de pacientes con enfermedades cardiovasculares con daños en l ...
Insiders
Mikael Dolsten ocupa el cargo de Director Científico y Presidente de Investigación en Pfizer Inc. El Dr. Dolsten también forma parte del consejo de administración de la Academia de Ciencias de Nueva York, Karyopharm Therapeutics, Inc. y la Fundación PhRMA, y es miembro de la Real Academia Sueca de Ciencias de la Ingeniería y de la Mesa Redonda de Investigación Gobierno-Universidad-Industria. En el pasado ocupó el cargo de director de OrbiMed Advisors LLC y socio de OrbiMed Advisors Private Equity (una filial de OrbiMed Advisors LLC), presidente de Wyeth Research, vicepresidente ejecutivo, jefe global de investigación y descubrimiento farmacéutico de Boehringer Ingelheim Pharmaceuticals, Inc. y vicepresidente senior de Wyeth Corp. y miembro del comité de beneficios, leyes y regulación de Wyeth Pharmaceuticals LLC. El Dr. Dolsten se doctoró en la Universidad de Lund.
Mikael Bodin currently works as a Sales Director at ARRIS Sweden AB.
Mr. Mikael H.
Lorsell is a Portfolio Manager at Alcur Fonder AB.
Mr. Lorsell was previously employed as an Analyst by Danske Bank A/S (Sweden), a Research Analyst by Erik Penser Bank AB, and a Research Analyst by Swedbank AB (Broker).
He has a bachelor's degree in economics from Stockholm University.
Mikael Søgaard worked as a Portfolio Manager at EGNS-Invest Investeringsforvaltningsselskab A from 2006 to 2011.
He also worked as an Equity Analyst at Sparinvest SA (Denmark).
Mikael Sandström worked as the Head of Products & Administrator at Cicero Fonder AB from 2015 to 2016.
Mikael Kadri is currently a Director at Grangex AB and a Partner at Trill Invest AB.
Previously, he worked as an Interim Chief Executive Officer at Monyx Asset Management AB in 2013-2014, and as a Portfolio Manager at Carnegie Fond AB in 2005-2006 and at Manticore Capital AB in 2006-2007.
Kadri is a graduate of Stockholm School of Economics.
Mikael Lyngsø is currently the Chief Executive Officer at Stibo Catalog A since 1995 and the Director at Hesehus A since 2019.
He previously worked as the Chief Executive Officer at Stibo Systems A, Director at Stibo Systems Ltd., and Software Developer at CCI Europe A.
Mr. Lyngsø completed his undergraduate degree from the University of Aarhus in 1989.
No hay resultados para esta búsqueda
- Bolsa de valores
- Búsqueda avanzada
- Mikael Dolsten